Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Xiaoxue LiuLing XueHua ZhangQingqing XuShichao ZhangSheng MaXiaoliang DingLinsheng LiuJi DongLifang QianWen XiaKun JiangChenrong HuangLiyan MiaoPublished in: Clinical drug investigation (2020)
CFDA registration numbers CTR20160096, CTR20160094, and CTR20140543 (www.chinadrugtrials.org.cn).